Trials / Recruiting
RecruitingNCT07214753
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
ItAlian, Multicenter, Observational, Prospective sTudy to Evaluate the acHievement of Clinical rEmission and immuNomodulation in Severe Eosinophilic Asthma Patients Treated With Benralizumab - the ATHENA Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 335 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
Detailed description
The ATHENA study aims to expand real-world evidence on benralizumab role in clinical practice, specifically evaluating its effectiveness in achieving clinical remission (complete and partial), as defined by SANI. Additionally, given the growing importance of biomarkers in asthma research, this study seeks to further investigate benralizumab immunological effects, potentially contributing to a deeper understanding of asthma pathophysiology and addressing existing knowledge conundrum. Additionally, the study will consolidate long-term safety data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | benralizumab | 30mg s.c. as per SmPC |
Timeline
- Start date
- 2025-12-20
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2025-10-09
- Last updated
- 2026-04-09
Locations
28 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT07214753. Inclusion in this directory is not an endorsement.